贝达药业：公司与杭州瑞普晨创科技有限公司在人多能干细胞向胰岛细胞诱导分化技术领域展开深入合作

Group 1 - Company has signed a strategic cooperation agreement with Hangzhou Ruipu Morning Technology Co., Ltd. to invest in the field of stem cell differentiation technology towards pancreatic cells [1] - The clinical research of RGB-5088 pancreatic cell injection for the treatment of type 1 diabetes is currently underway [1] - Company will monitor developments in other areas and will disclose any significant collaborations in a timely manner [1] Group 2 - Company has established a strategic partnership with Shengsi Biotech to enter the hemophilia treatment sector, which is characterized by long-term medication needs and strong customer loyalty [3] - The inquiry from investors highlights the potential for the company to develop long-term medication projects beyond oncology, such as hypertension, diabetes, weight loss, and anti-lipid drugs [3]